Form 4: Moderna Director Elizabeth E. Tallett Reports Stock Option and Restricted Stock Unit Grant

Director Elizabeth E. Tallett reports the acquisition of stock options and restricted stock units in Moderna, Inc.

Summary

• Elizabeth E. Tallett, a director of Moderna, Inc., reported the acquisition of stock options and restricted stock units on April 30, 2025.
• Tallett acquired 19,134 stock options with an exercise price of $28.54, which will fully vest on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, contingent upon continued service.
• She also acquired 4,058 restricted stock units, which convert into common stock on a one-for-one basis and will vest fully on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning director interests with shareholders. There are no immediate financial implications, but it signals confidence in the company's future.

Positives

• The grant of stock options and restricted stock units to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to Moderna's long-term success.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in high-growth sectors like biotechnology.
• Companies like BioNTech and Pfizer also utilize stock options and restricted stock units as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders may view the grant of stock options and restricted stock units positively, as it aligns the director's interests with the company's long-term success.
• Employees may see it as a sign of the company's commitment to incentivizing and retaining key personnel.

Key Dates

Keywords

Moderna, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, Tallett, MRNA